T1	DISO 1 29	Malaria por Plasmodium vivax
#1	AnnotatorNotes T1	C0024537; Malaria, Vivax; Disease or Syndrome
T2	CHEM 86 96	primaquina
#2	AnnotatorNotes T2	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T3	CHEM 183 185	CQ
#3	AnnotatorNotes T3	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T4	CHEM 113 123	cloroquina
#4	AnnotatorNotes T4	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T5	CHEM 201 203	PQ
#5	AnnotatorNotes T5	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T6	CHEM 171 181	Cloroquina
#6	AnnotatorNotes T6	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T7	CHEM 189 199	primaquina
#7	AnnotatorNotes T7	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T8	DISO 240 267	malaria vivax no complicada
#8	AnnotatorNotes T8	C0348263; Plasmodium vivax malaria without complication; Disease or Syndrome
T9	PROC 290 317	evaluaciones de su eficacia
#9	AnnotatorNotes T9	C1707887; Efficacy Study; Research Activity
T10	DISO 362 375	malaria vivax
#10	AnnotatorNotes T10	C0024537; Malaria, Vivax; Disease or Syndrome
T11	PROC 730 741	tratamiento
#11	AnnotatorNotes T11	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T12	PROC 488 508	tratamiento estándar
#12	AnnotatorNotes T12	C2936643; Standard of Care; Health Care Activity
T13	PROC 568 588	tratamiento estándar
#13	AnnotatorNotes T13	C2936643; Standard of Care; Health Care Activity
T14	DISO 692 708	efectos adversos
#14	AnnotatorNotes T14	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T15	CHEM 742 744	CQ
#15	AnnotatorNotes T15	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T16	PROC 1000 1011	Seguimiento
#16	AnnotatorNotes T16	C1522577; Follow up; Health Care Activity | C0420316; Other follow-up; Health Care Activity
T17	DISO 1328 1339	parasitemia
#17	AnnotatorNotes T17	C0242723; Parasitemia; Disease or Syndrome
T18	PROC 1366 1377	tratamiento
#18	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	PROC 1505 1516	tratamiento
#19	AnnotatorNotes T19	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T20	DISO 44 56	ataque agudo
T21	PROC 230 236	tratar
#20	AnnotatorNotes T21	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T22	CHEM 509 511	CQ
#21	AnnotatorNotes T22	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T23	PROC 1144 1155	Se trataron
#22	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	CHEM 1382 1384	CQ
#23	AnnotatorNotes T24	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T25	CHEM 1517 1519	CQ
#24	AnnotatorNotes T25	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T26	PROC 1694 1721	administración concomitante
#25	AnnotatorNotes T26	C1707479; Concomitant Therapy; Therapeutic or Preventive Procedure
T27	CHEM 512 514	PQ
#26	AnnotatorNotes T27	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T28	PROC 543 563	comparar la eficacia
#27	AnnotatorNotes T28	C1707887; Efficacy Study; Research Activity
T29	CHEM 648 650	CQ
#28	AnnotatorNotes T29	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T30	CHEM 669 671	PQ
#29	AnnotatorNotes T30	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T31	CHEM 745 747	PQ
#30	AnnotatorNotes T31	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T32	PROC 772 810	Diseño aleatorio, controlado, no ciego
#31	AnnotatorNotes T32	C0034656; Randomization; Research Activity + C1709323; Open Label Study; Research Activity + C0681867; Controlled Study; Research Activity
T33	CHEM 855 857	PQ
#32	AnnotatorNotes T33	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T34	CHEM 894 896	CQ
#33	AnnotatorNotes T34	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T35	CHEM 938 940	PQ
#34	AnnotatorNotes T35	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T36	CHEM 1520 1522	PQ
#35	AnnotatorNotes T36	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T37	CHEM 1545 1547	PQ
#36	AnnotatorNotes T37	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T38	CHEM 1589 1591	CQ
#37	AnnotatorNotes T38	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T39	CHEM 1592 1594	PQ
#38	AnnotatorNotes T39	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T40	CHEM 1725 1727	CQ
#39	AnnotatorNotes T40	C0008269; chloroquine; Organic Chemical · Pharmacologic Substance
T41	CHEM 1730 1732	PQ
#40	AnnotatorNotes T41	C0033126; primaquine; Organic Chemical · Pharmacologic Substance
T42	PHYS 31 39	curación
#41	AnnotatorNotes T42	C2004454; Recovery - healing process; Organism Function
T43	Dose 61 71	tres dosis
T44	Dose 99 109	dosis fija
#42	AnnotatorNotes T44	C5548493; Fixed dose; Quantitative Concept
T45	Date 146 150	2003
T46	Date 151 155	2004
T49	Dose 859 875	45, 105 y 210 mg
T50	Dose 898 905	1500 mg
T51	Duration 910 918	48 horas
T52	LIVB 942 951	Pacientes
#43	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T54	Duration 1020 1027	28 días
T55	LIVB 1160 1169	pacientes
#44	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T56	Duration 1354 1362	24 horas
T57	LIVB 1399 1408	pacientes
#45	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	Duration 1413 1421	48 horas
T59	Duration 1434 1442	72 horas
T60	LIVB 1465 1474	pacientes
#46	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	Dose 1527 1541	dosis variable
T63	LIVB 13 29	Plasmodium vivax
#47	AnnotatorNotes T63	C0032154; Plasmodium vivax; Eukaryote
R1	Causes Arg1:T63 Arg2:T1	
R2	Has_Dose_or_Strength Arg1:T2 Arg2:T43	
R3	Has_Dose_or_Strength Arg1:T4 Arg2:T44	
R4	Causes Arg1:T1 Arg2:T20	
R5	Used_for Arg1:T6 Arg2:T21	
R6	Causes Arg1:T2 Arg2:T42	
R7	Used_for Arg1:T3 Arg2:T21	
T47	Neg_cue 254 256	no
T48	Quantifier_or_Qualifier 257 267	complicada
A1	Assertion T48 Negated
R10	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T48	
R11	Negation Arg1:T47 Arg2:T48	
T53	CONC 1551 1557	afectó
A2	Assertion T53 Negated
T62	Neg_cue 1548 1550	no
R12	Negation Arg1:T62 Arg2:T53	
T64	Observation 437 458	respuesta terapéutica
R13	Overlap Arg1:T64 Arg2:T12	
R14	Used_for Arg1:T22 Arg2:T12	
R15	Used_for Arg1:T29 Arg2:T13	
R16	Used_for Arg1:T15 Arg2:T11	
R17	Causes Arg1:T11 Arg2:T14	
R18	Has_Dose_or_Strength Arg1:T33 Arg2:T49	
R19	Has_Dose_or_Strength Arg1:T34 Arg2:T50	
R20	Has_Duration_or_Interval Arg1:T34 Arg2:T51	
R21	Combined_with Arg1:T34 Arg2:T35	
R22	Combined_with Arg1:T2 Arg2:T4	
R23	Combined_with Arg1:T6 Arg2:T7	
R24	Combined_with Arg1:T6 Arg2:T5	
R25	Combined_with Arg1:T3 Arg2:T7	
R26	Combined_with Arg1:T3 Arg2:T5	
R8	Combined_with Arg1:T22 Arg2:T27	
R9	Combined_with Arg1:T29 Arg2:T30	
R27	Combined_with Arg1:T15 Arg2:T31	
R28	Has_Duration_or_Interval Arg1:T35 Arg2:T51	
T65	PROC 952 960	captados
#48	AnnotatorNotes T65	C0242802; Patient Selection; Research Activity (?)
T66	Quantifier_or_Qualifier 961 977	consecutivamente
R29	Has_Quantifier_or_Qualifier Arg1:T65 Arg2:T66	
R30	Has_Duration_or_Interval Arg1:T16 Arg2:T54	
T67	Observation 1032 1053	respuesta terapéutica
#49	AnnotatorNotes T64	C4055223; Clinical Response; Finding
T68	Quantifier_or_Qualifier 459 471	antimalárica
R31	Has_Quantifier_or_Qualifier Arg1:T64 Arg2:T68	
#50	AnnotatorNotes T67	C4055223; Clinical Response; Finding
T69	Quantifier_or_Qualifier 1054 1066	antimalárica
R32	Has_Quantifier_or_Qualifier Arg1:T67 Arg2:T69	
T70	Observation 1111 1129	respuesta adecuada
#51	AnnotatorNotes T70	C0184785; Good therapeutic response; Finding (?)
R33	Has_Dose_or_Strength Arg1:T37 Arg2:T61	
R34	Causes Arg1:T37 Arg2:T53	
T71	Observation 1475 1516	respondieron adecuadamente al tratamiento
#52	AnnotatorNotes T71	C0184785; Good therapeutic response; Finding (?)
R35	Experiences Arg1:T60 Arg2:T71	
R36	Experiences Arg1:T60 Arg2:T19	
R37	Used_for Arg1:T24 Arg2:T18	
R38	Has_Duration_or_Interval Arg1:T18 Arg2:T56	
T72	Neg_cue 1340 1350	se eliminó
A3	Assertion T17 Negated
R39	Negation Arg1:T72 Arg2:T17	
R40	Overlap Arg1:T17 Arg2:T56	
R41	Experiences Arg1:T57 Arg2:T17	
R42	Experiences Arg1:T57 Arg2:T18	
R43	Overlap Arg1:T17 Arg2:T58	
R44	Overlap Arg1:T17 Arg2:T59	
R45	Has_Duration_or_Interval Arg1:T18 Arg2:T58	
R46	Has_Duration_or_Interval Arg1:T18 Arg2:T59	
R47	Experiences Arg1:T55 Arg2:T23	
T73	Observation 1175 1196	respuesta terapéutica
#53	AnnotatorNotes T73	C4055223; Clinical Response; Finding
R48	Experiences Arg1:T55 Arg2:T73	
T74	Quantifier_or_Qualifier 1197 1209	antimalárica
R49	Has_Quantifier_or_Qualifier Arg1:T73 Arg2:T74	
T75	Observation 1082 1094	falla precoz
T76	Observation 1096 1108	falla tardía
R50	Used_for Arg1:T25 Arg2:T19	
R51	Combined_with Arg1:T25 Arg2:T36	
R52	Combined_with Arg1:T38 Arg2:T39	
R53	Used_for Arg1:T40 Arg2:T26	
R54	Combined_with Arg1:T40 Arg2:T41	
T77	DISO 348 355	clínica
#54	AnnotatorNotes T77	C0037088; Signs and Symptoms; Sign or Symptom
T78	DISO 1231 1245	cuadro clínico
#55	AnnotatorNotes T78	C0037088; Signs and Symptoms; Sign or Symptom
T79	Observation 1563 1572	respuesta
#56	AnnotatorNotes T79	C1319171; Medication response; Finding
R55	Causes Arg1:T10 Arg2:T77	
R56	Experiences Arg1:T52 Arg2:T65	
#57	AnnotatorNotes T66	C1707491; Consecutive; Qualitative Concept
#58	AnnotatorNotes T53	C0521102; Interferes with; Functional Concept
R57	Overlap Arg1:T37 Arg2:T79	
#59	AnnotatorNotes T48	C0231242; Complicated; Functional Concept
#60	AnnotatorNotes T68	C4552582; Antimalarial (disposition); Qualitative Concept
#61	AnnotatorNotes T74	C4552582; Antimalarial (disposition); Qualitative Concept
#62	AnnotatorNotes T69	C4552582; Antimalarial (disposition); Qualitative Concept
#63	AnnotatorNotes T75	C5554308; Early treatment failure; Finding
A4	Experiencer T60 Patient
A5	Experiencer T57 Patient
A6	Experiencer T52 Patient
A7	Experiencer T55 Patient
